ASCO GI 2025 | Dr. Xiufeng Liu’s In-Depth Analysis of CheckMate 9DW and CARES-310 Study Updates

ASCO GI 2025 | Dr. Xiufeng Liu’s In-Depth Analysis of CheckMate 9DW and CARES-310 Study Updates

2025.02.24
The landscape of systemic therapy for hepatocellular carcinoma (HCC) has undergone a major transformation, shifting from single-agent targeted or immunotherapies to dual immune checkpoint inhibitors and immune-targeted combination regimens. The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), held on January 23, 2025, highlighted two pivotal studies—CheckMate 9DW and CARES-310—focusing on dual immunotherapy strategies for previously untreated unresectable hepatocellular carcinoma (uHCC) and the impact of viral infection status on treatment outcomes.
Dr. Xiangrui Meng: “VEGF-TKI + PD-1 Inhibitor + Chemotherapy” as a Potential New Treatment Option for PD-L1-Negative Advanced Gastric Cancer

Dr. Xiangrui Meng: “VEGF-TKI + PD-1 Inhibitor + Chemotherapy” as a Potential New Treatment Option for PD-L1-Negative Advanced Gastric Cancer

2025.02.24
In recent years, the emergence and breakthrough progress of multiple targeted and immunotherapy drugs, along with their combination regimens, have brought significant transformation to the systemic treatment of esophageal and gastric cancer. The field has evolved from monotherapy with targeted or immune agents to an era of dual or multi-immunotherapy combinations.
Today is MPN Awareness Day!

Today is MPN Awareness Day!

2025.02.21
We come together globally to raise awareness about Myeloproliferative Neoplasms (MPNs) and to support those impacted by these rare blood cancers. By uniting in purpose, we can drive forward research,…
In-Depth Analysis丨Dr. Wei Li & Dr. Shaohua Zhang: First-Line Treatment Options for Patients with Recurrent Metastatic Triple-Negative Breast Cancer

In-Depth Analysis丨Dr. Wei Li & Dr. Shaohua Zhang: First-Line Treatment Options for Patients with Recurrent Metastatic Triple-Negative Breast Cancer

2025.02.21
For patients with recurrent metastatic triple-negative breast cancer (TNBC), would you choose "chemotherapy + immunotherapy" or "ADC" for treatment? At the 2024 Breast Cancer Summer Forum·Northern Salon "In-Depth Analysis" session, Dr. Wei Li from Jiangsu Provincial People's Hospital and Dr. Shaohua Zhang from the Chinese PLA General Hospital presented their respective viewpoints. Dr. Wei Li expressed a preference for "chemotherapy + immunotherapy," while Dr. Shaohua Zhang opted for "ADC." Following the session, Oncology Frontier invited the two experts to elaborate on their perspectives.
News of ASH：Gut Microbiota and CAR-T Therapy

News of ASH：Gut Microbiota and CAR-T Therapy

2025.02.20
The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, bringing together over 30,000 experts and scholars worldwide. Through meticulously curated sessions, the conference provided valuable insights into fundamental research, innovative therapies, and disease management in hematology. To distill the essence of ASH and capture the latest advancements in the field, Hematology Frontier launched the News of ASH series, compiling key takeaways from ASH's official reports to present cutting-edge developments and significant discoveries to readers.
ASCO GI 2025 | Dr. Jin Li: A New Era for Chemotherapy as the First Oral Paclitaxel Demonstrates Non-Inferiority to Intravenous Administration

ASCO GI 2025 | Dr. Jin Li: A New Era for Chemotherapy as the First Oral Paclitaxel Demonstrates Non-Inferiority to Intravenous Administration

2025.02.19
The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) took place from January 23 to 25 in San Francisco, bringing together the latest advancements in digestive tract oncology. Paclitaxel remains one of the most important chemotherapeutic agents for gastric cancer treatment. However, the traditional intravenous (IV) formulation has long been associated with significant adverse effects. Chinese researchers have continued to optimize the structure and formulation of paclitaxel, aiming for better efficacy and safety, ultimately leading to the successful development and approval of the world's first oral paclitaxel solution.